{"id":2236,"date":"2020-11-09T15:58:19","date_gmt":"2020-11-09T15:58:19","guid":{"rendered":"https:\/\/www.almacgroup.com\/diagnostics\/?post_type=diagnostic_resource&#038;p=2236"},"modified":"2025-02-26T09:12:14","modified_gmt":"2025-02-26T09:12:14","slug":"the-almac-advantage-post-brexit-northern-ireland-ivd-landscape","status":"publish","type":"diagnostic_resource","link":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/","title":{"rendered":"The Almac Advantage \u2013 Post-Brexit Northern Ireland IVD Landscape"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\">Almac is uniquely placed to act as \u201cone stop shop\u201d with easy access to both<br>the EU and UK for biomarker clinical trial support and CDx development &amp;<br>commercialisation<\/h3>\n\n\n\n<div style=\"height:38px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><img decoding=\"async\" class=\"alignleft wp-image-53035 lazyload\" data-src=\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/stewart-mcwilliams.jpg\" alt=\"The increasing uptake of RNA-Seq as the technology of choice in biomarker discovery\" width=\"150\" height=\"150\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" style=\"--smush-placeholder-width: 150px; --smush-placeholder-aspect-ratio: 150\/150;\"><noscript><img decoding=\"async\" class=\"alignleft wp-image-53035\" src=\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/stewart-mcwilliams.jpg\" alt=\"The increasing uptake of RNA-Seq as the technology of choice in biomarker discovery\" width=\"150\" height=\"150\"><\/noscript><\/p>\n<h2>Dr Stewart McWilliams<\/h2>\n<p><strong>Global VP of Quality &amp; Regulatory Affairs, Almac Diagnostic Services<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Almac-Voice-Almac-Advantage.pdf\"><img decoding=\"async\" class=\"wp-image-53119 size-medium alignright lazyload\" data-src=\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Almac-Voice-Almac-Advantage-1.jpg\" alt=\"The increasing uptake of RNA-Seq as the technology of choice in biomarker discovery\" width=\"213\" height=\"300\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" style=\"--smush-placeholder-width: 213px; --smush-placeholder-aspect-ratio: 213\/300;\"><noscript><img decoding=\"async\" class=\"wp-image-53119 size-medium alignright\" src=\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Almac-Voice-Almac-Advantage-1.jpg\" alt=\"The increasing uptake of RNA-Seq as the technology of choice in biomarker discovery\" width=\"213\" height=\"300\"><\/noscript><\/a><\/p>\n<p><a class=\"c-btn c-btn--purple\" title=\"Download the article\" href=\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Almac-Voice-Almac-Advantage.pdf\">Download the article<\/a><\/p>\n<p align=\"LEFT\"><strong>Background<\/strong><\/p>\n<p>Due to the special status that Northern Ireland has been granted as part of the EU Withdrawal Agreement between EU27 and UK, once the transition period ends (and regardless of whether the EU and UK have concluded a trade agreement by then), Northern Ireland will continue to adhere to EU rules on the regulation of medicinal products, medical devices and the movement of goods. This part of the Withdrawal Agreement is known as the \u201cNorthern Ireland Protocol\u201d.<\/p>\n<p>This puts Almac in a unique position to allow clients unfettered and flexible access to support their biomarker clinical trial and CDx development in both the UK &amp; European markets.<\/p>\n<p align=\"LEFT\"><strong>New MHRA Guidance for Medical Devices<\/strong><\/p>\n<p>MHRA guidance for regulating medical devices in the UK from the end of the Brexit transition period (31st December 2020), was published on 1st September 2020. Under the terms of the Northern Ireland Protocol, from 1 January 2021, the rules for placing medical devices on the Northern Ireland market will differ from those applicable to Great Britain and will remain aligned with those of the EU.<\/p>\n<p>The Northern Ireland Protocol will offer Northern Ireland-based companies, like Almac, the opportunity to effectively act as if they are still within the EU with respect to compliance with EU In Vitro Diagnostic (IVD) Regulations and EU Clinical Trial Regulations while still being able to easily access the UK market. In other words, the best of both worlds.<\/p>\n<p>As a result, for in vitro diagnostics being used in NI for clinical trials, Almac will remain in compliance with current EU directives and incoming IVD regulations (full compliance to which must be achieved by 26 May 2022 respectively, in line with the EU\u2019s implementation timeline.)<\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Almac-Voice-Almac-Advantage-box-image-e1604936435294.jpg\"><img decoding=\"async\" class=\"aligncenter wp-image-53077 lazyload\" data-src=\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Almac-Voice-Almac-Advantage-box-image-e1604936435294.jpg\" alt=\"The increasing uptake of RNA-Seq as the technology of choice in biomarker discovery\" width=\"650\" height=\"266\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" style=\"--smush-placeholder-width: 650px; --smush-placeholder-aspect-ratio: 650\/266;\"><noscript><img decoding=\"async\" class=\"aligncenter wp-image-53077\" src=\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Almac-Voice-Almac-Advantage-box-image-e1604936435294.jpg\" alt=\"The increasing uptake of RNA-Seq as the technology of choice in biomarker discovery\" width=\"650\" height=\"266\"><\/noscript><\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>The Almac Advantage &#038; Northern Ireland<\/strong><\/p>\n<p>Almac Group has been working under the current EU directives for many years and Almac Diagnostic Services has been planning for the IVDR for several years. We will be fully compliant with the EU IVDR by the May 2022 deadline. Our customers, who are currently utilising our services, can expect continuity with respect to levels of service and hassle-free regulatory transition for their assays to the new EU regulation.<\/p>\n<p>From the 31st June 2023 for IVD\u2019s utilised within the UK a new UKCA mark will replace the CE-mark and will be required to be displayed on all devices. Manufacturers of IVD\u2019s, such as Almac, who are located in Northern Ireland, will still be able to register all devices with the MHRA.<\/p>\n<p>As per the current guidance from MHRA, a Northern Ireland-based manufacturer upon registration of an IVD with the MHRA, can then freely supply the device between Northern Ireland and Great Britain with no further registration required.<\/p>\n<p>This is a huge benefit for Almac\u2019s customers allowing Almac Diagnostic Services to act effectively as a \u2018one stop shop\u2019 for UK and EU clinical trial support activities such as clinical testing and in vitro diagnostic (IVD) development from our global headquarters based in Craigavon, Northern Ireland.<\/p>\n<p><strong>Further Brexit Information from Almac Group:<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/www.almacgroup.com\/post-brexit-the-almac-advantage\/\"><img decoding=\"async\" class=\"aligncenter wp-image-53077 lazyload\" data-src=\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Dx-almac-voice-brexit-banner.png\" alt=\"The increasing uptake of RNA-Seq as the technology of choice in biomarker discovery\" width=\"650\" height=\"266\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" style=\"--smush-placeholder-width: 650px; --smush-placeholder-aspect-ratio: 650\/266;\"><noscript><img decoding=\"async\" class=\"aligncenter wp-image-53077\" src=\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Dx-almac-voice-brexit-banner.png\" alt=\"The increasing uptake of RNA-Seq as the technology of choice in biomarker discovery\" width=\"650\" height=\"266\"><\/noscript><\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>About the Author<\/strong><\/p>\n<p>Stewart McWilliams leads the Quality Management and In vitro Diagnostic (IVD) Regulatory affairs activities at Almac Diagnostic Services. The team works with pharmaceutical industry clients on the Quality and Regulatory aspects of CDx Development and Commercialisation. They are also responsible for Almac Diagnostic Services\u2019 Laboratory Quality Management systems ensuring compliance with ISO13485, CLIA (Federal and New York State CLEP), ISO17025, ISO15189 and the College of American Pathologists (CAP) accreditation requirements.<\/p>\n<p>&nbsp;<\/p>\n\n","protected":false},"featured_media":0,"template":"","diagnostics_type":[478],"class_list":["post-2236","diagnostic_resource","type-diagnostic_resource","status-publish","hentry","diagnostics_type-diagnostics-almac-voice"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.3.1 (Yoast SEO v26.3) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Almac Advantage \u2013 Post-Brexit Northern Ireland IVD Landscape - Diagnostic Services<\/title>\n<meta name=\"description\" content=\"Almac is uniquely placed to act as \u201cone stop shop\u201d with easy access to both the EU and UK for biomarker clinical trial support and CDx development &amp;commercialisation\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Almac Advantage \u2013 Post-Brexit Northern Ireland IVD Landscape\" \/>\n<meta property=\"og:description\" content=\"Almac is uniquely placed to act as \u201cone stop shop\u201d with easy access to both the EU and UK for biomarker clinical trial support and CDx development &amp;commercialisation\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/\" \/>\n<meta property=\"og:site_name\" content=\"Diagnostic Services\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-26T09:12:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Almac_Logo-e1698941154737.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"100\" \/>\n\t<meta property=\"og:image:height\" content=\"52\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/\",\"url\":\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/\",\"name\":\"The Almac Advantage \u2013 Post-Brexit Northern Ireland IVD Landscape - Diagnostic Services\",\"isPartOf\":{\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/stewart-mcwilliams.jpg\",\"datePublished\":\"2020-11-09T15:58:19+00:00\",\"dateModified\":\"2025-02-26T09:12:14+00:00\",\"description\":\"Almac is uniquely placed to act as \u201cone stop shop\u201d with easy access to both the EU and UK for biomarker clinical trial support and CDx development &commercialisation\",\"breadcrumb\":{\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.almacgroup.com\/diagnostics\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Almac Advantage \u2013 Post-Brexit Northern Ireland IVD Landscape\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#website\",\"url\":\"https:\/\/www.almacgroup.com\/diagnostics\/\",\"name\":\"Diagnostic Services\",\"description\":\"Just another Almac Core Sites site\",\"publisher\":{\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.almacgroup.com\/diagnostics\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#organization\",\"name\":\"Almac Group Ltd\",\"url\":\"https:\/\/www.almacgroup.com\/diagnostics\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/04\/almac-logo-with-strapline.jpg\",\"contentUrl\":\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/04\/almac-logo-with-strapline.jpg\",\"width\":643,\"height\":296,\"caption\":\"Almac Group Ltd\"},\"image\":{\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Almac Advantage \u2013 Post-Brexit Northern Ireland IVD Landscape - Diagnostic Services","description":"Almac is uniquely placed to act as \u201cone stop shop\u201d with easy access to both the EU and UK for biomarker clinical trial support and CDx development &commercialisation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/","og_locale":"en_GB","og_type":"article","og_title":"The Almac Advantage \u2013 Post-Brexit Northern Ireland IVD Landscape","og_description":"Almac is uniquely placed to act as \u201cone stop shop\u201d with easy access to both the EU and UK for biomarker clinical trial support and CDx development &commercialisation","og_url":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/","og_site_name":"Diagnostic Services","article_modified_time":"2025-02-26T09:12:14+00:00","og_image":[{"width":100,"height":52,"url":"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Almac_Logo-e1698941154737.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/","url":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/","name":"The Almac Advantage \u2013 Post-Brexit Northern Ireland IVD Landscape - Diagnostic Services","isPartOf":{"@id":"https:\/\/www.almacgroup.com\/diagnostics\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/#primaryimage"},"image":{"@id":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/#primaryimage"},"thumbnailUrl":"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/stewart-mcwilliams.jpg","datePublished":"2020-11-09T15:58:19+00:00","dateModified":"2025-02-26T09:12:14+00:00","description":"Almac is uniquely placed to act as \u201cone stop shop\u201d with easy access to both the EU and UK for biomarker clinical trial support and CDx development &commercialisation","breadcrumb":{"@id":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/the-almac-advantage-post-brexit-northern-ireland-ivd-landscape\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.almacgroup.com\/diagnostics\/"},{"@type":"ListItem","position":2,"name":"The Almac Advantage \u2013 Post-Brexit Northern Ireland IVD Landscape"}]},{"@type":"WebSite","@id":"https:\/\/www.almacgroup.com\/diagnostics\/#website","url":"https:\/\/www.almacgroup.com\/diagnostics\/","name":"Diagnostic Services","description":"Just another Almac Core Sites site","publisher":{"@id":"https:\/\/www.almacgroup.com\/diagnostics\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.almacgroup.com\/diagnostics\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.almacgroup.com\/diagnostics\/#organization","name":"Almac Group Ltd","url":"https:\/\/www.almacgroup.com\/diagnostics\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.almacgroup.com\/diagnostics\/#\/schema\/logo\/image\/","url":"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/04\/almac-logo-with-strapline.jpg","contentUrl":"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/04\/almac-logo-with-strapline.jpg","width":643,"height":296,"caption":"Almac Group Ltd"},"image":{"@id":"https:\/\/www.almacgroup.com\/diagnostics\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/diagnostic_resource\/2236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/diagnostic_resource"}],"about":[{"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/types\/diagnostic_resource"}],"wp:attachment":[{"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/media?parent=2236"}],"wp:term":[{"taxonomy":"diagnostics_type","embeddable":true,"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/diagnostics_type?post=2236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}